作为第一个双功能TREM2调节器:受体激活和除抑制
bioRxiv : the preprint server for biology
|September 5, 2025
概括
一种名为As48的新药激活TREM2信号并阻止其脱落,通过增强微质功能和大脑修复机制,为阿尔茨海默病提供一种新的治疗策略.
科学领域:
- 神经科学
- 免疫学
- 药理学
背景情况:
- 在骨髓细胞2 (TREM2) 上表达的触发受体功能障碍与阿尔茨海默病 (AD) 发病有关.
- 通过ADAM介导的TREM2泄露降低了受体信号的有效性,这是当前治疗的挑战.
研究的目的:
- 确定调节TREM2活动的新型小分子.
- 开发用于阿尔茨海默病治疗的增强TREM2信号和防止受体脱落的疗法.
主要方法:
- 亲和选择质谱 (AS-MS) 选以确定TREM2配体.
- 生物物理验证,细胞检测 (SYK化,细胞化),分子对接和分子动力学模拟.
- 评估As48对TREM2ectodomain脱落和蛋白酶活性的影响 (ADAM10/17).
主要成果:
- 一个新的小分子As48,与TREM1相比具有较高的亲和力和选择性.
- As48作为TREM2激动剂,增强微细胞和SYK酸化.
- 在不影响蛋白酶活性的情况下,As48通过在分裂部位附近的形状限制来抑制TREM2脱落.
- As48显示出有利的药理动力学和大脑透性的潜力.
结论:
- As48是第一个能够同时激活TREM2信号并抑制其分泌的小分子.
- 在神经炎症和阿尔茨海默病药物发现中,AS48代表了TREM2调制的范式转变.
- 在治疗神经退行性疾病方面,As48的双重作用机制具有显著的转化意义.
更多相关视频
12:09Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
Published on: February 28, 2019
9.9K
06:21An Ecdysone Receptor-based Singular Gene Switch for Deliberate Expression of Transgene with Robustness, Reversibility, and Negligible Leakiness
Published on: May 7, 2018
6.6K
相关概念视频
Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K
The Two-State Receptor Model
2.4K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
2.4K
Transducer Mechanism: G Protein–Coupled Receptors
2.4K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
GPCRs are also called heptahelical,...
2.4K
Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K
GPCR Desensitization
6.4K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.4K
Spare Receptors
3.8K
Some receptors remain unoccupied even when an agonist produces a maximal response. Such empty ones are called spare receptors. In presence of spare receptors the maximum effect of an agonist drug is achieved with fewer than 100% of the receptors being occupied. To determine the presence of spare receptors, scientists often compare the concentration of the drug needed to produce 50% of the maximum effect (EC50) with the concentration of the drug needed to occupy 50% of the receptors (Kd). If the...
3.8K
